Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review

Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review

Abstract Background Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disease. The economic burden of MS is substantial, and the high cost of Disease-modifying drugs (DMDs) prices are the main drivers of healthcare expenditures. We conducted a systematic review of studies evaluating...

Full description

Bibliographic Details
Main Authors: Nasrin Abulhasanbeigi Gallehzan, Majid Khosravi, Khosro Jamebozorgi, Nazanin Mir, Habib Jalilian, Samira Soleimanpour, Saeed Hoseini, Aziz Rezapour, Abbas Eshraghi
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Health Economics Review
Subjects:
Disease-modifying drugs
Relapsing–remitting multiple sclerosis
Cost-utility analysis
Cost-effectiveness analysis
Online Access:https://doi.org/10.1186/s13561-024-00478-7

Internet

https://doi.org/10.1186/s13561-024-00478-7

Similar Items